|78.60||-0.7000||-0.88%||Vol 461.47K||1Y Perf 2.87%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||109.14||Analyst Rating||Strong Buy 1.38|
|Potential %||38.86||Finscreener Ranking||★★★★★ 62.20|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 57.71|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 78.16|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||33.22||Earnings Rating||Neutral|
|Market Cap||14.41B||Earnings Date||4th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||-0.11|
|EPS Growth Next 5 Years %||31.70|
|Avg. Weekly Volume||865.36K|
|Avg. Monthly Volume||1.37M|
|Avg. Quarterly Volume||1.13M|
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 78.6 per share at the end of the most recent trading day (a -0.88% change compared to the prior day closing price) with a volume of 463.16K shares and market capitalization of 14.41B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.
The one-year performance of BioMarin Pharmaceutical Inc. stock is 2.87%, while year-to-date (YTD) performance is -10.37%. BMRN stock has a five-year performance of -19.3%. Its 52-week range is between 71.65 and 92.57, which gives BMRN stock a 52-week price range ratio of 33.22%
BioMarin Pharmaceutical Inc. currently has a PE ratio of 18.00, a price-to-book (PB) ratio of 3.36, a price-to-sale (PS) ratio of 7.40, a price to cashflow ratio of 55.50, a PEG ratio of 2.32, a ROA of 14.57%, a ROC of 16.81% and a ROE of 21.87%. The company’s profit margin is 43.71%, its EBITDA margin is 3.50%, and its revenue ttm is $1.92 Billion , which makes it $10.45 revenue per share.
Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.38), with a target price of $109.14, which is +38.86% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioMarin Pharmaceutical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.19, ATR14 : 1.95, CCI20 : -28.83, Chaikin Money Flow : 0.02, MACD : -0.16, Money Flow Index : 47.90, ROC : 2.48, RSI : 49.77, STOCH (14,3) : 45.57, STOCH RSI : 0.73, UO : 47.42, Williams %R : -54.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Brian Mueller (Sold 0 shares of value $-189 395 ), Brian Mueller (Sold 6 709 shares of value $533 366 ), Elaine J. Heron (Sold 0 shares of value $-794 700 ), G. Eric Davis (Sold 0 shares of value $-71 761 ), G. Eric Davis (Sold 12 900 shares of value $1 004 654 ), Jean-Jacques Bienaime (Sold 0 shares of value $-3 770 619 ), Jean-Jacques Bienaime (Sold 142 513 shares of value $11 448 862 ), Jeffrey R. Ajer (Sold 7 799 shares of value $606 294 ), Michael G. Grey (Sold 0 shares of value $-132 450 ), Michael G. Grey (Sold 5 000 shares of value $381 400 ), V. Bryan Lawlis (Sold 0 shares of value $-397 350 ), V. Bryan Lawlis (Sold 15 000 shares of value $1 232 325 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.